Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns
In September 2023, ECDC updated its COVID-19 vaccination coverage data analysis process, in view of the evolving timing and objective of the vaccination campaigns in the 2023–24 season in the EU/EEA. This report presents an interim description of COVID-19 vaccine coverage in the EU/EEA between 1 September 2023 and 15 April 2024.
Executive Summary
In September 2023, ECDC updated its COVID-19 vaccination coverage data analysis process, in view of the evolving timing and objective of the 2023–24 season vaccination campaigns in the European Union/European Economic Area (EU/EEA). This report presents an interim description of COVID-19 vaccine coverage in the EU/EEA between 1 September 2023 and 15 April 2024.
During the reporting period, 27 of 30 EU/EEA countries reported data on COVID-19 vaccination coverage for at least one target group (people aged 60 years and above, people aged 80 years and above, healthcare workers, individuals with chronic conditions, pregnant women).
During this period, approximately 28.1 million people aged 60 years and above received one COVID-19 vaccine dose. Approximately seven million people aged 80 years and above received one COVID-19 vaccine dose.
Among the 27 reporting countries, six countries reported a vaccination coverage ≥50% for the age group 60 years and above, while nine countries reported a vaccination coverage ≥50% for the age group 80 years and above.
The median COVID-19 vaccination coverage among people aged 60 years and above was 12.0% (range: 0.01–66.1%), with high variation among countries. For people aged 80 years and above, the median coverage was 17.1% (range: 0.01–89.3%), with high variation among countries.
Most of the approximately 31 million COVID-19 vaccine doses administered in the EU/EEA during this period in the overall population were the Comirnaty Omicron XBB.1.5 (Pfizer BioNTech) vaccine (around 25.5 million doses; 82.1% of the total doses administered); for 14.5% of the doses, the product was reported as unknown.
These preliminary results must be interpreted with caution. Higher degrees of data consolidation and data completeness are expected in the coming months.